Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte S with Dextrose 5% is an intravenous solution providing electrolytes and calories. Dextrose supplies glucose for cellular energy metabolism, while electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure. Acetate and gluconate are metabolized to bicarbonate, providing alkalinizing effect.
Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.
Fluid and electrolyte replacement,Source of calories (dextrose) for parenteral nutrition,Treatment of metabolic acidosis (due to acetate/gluconate content)
FDA-approved: For intravenous administration as a source of water, electrolytes, and calories in patients requiring fluid and electrolyte replacement.,Off-label: Not typically used off-label; primarily for maintenance or replacement therapy.
Intravenous infusion; dose determined by fluid and electrolyte requirements. Typical adult maintenance: 100-200 m L/h (2.4-4.8 L/day) depending on clinical status.
Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.
Not applicable for the combination; individual components: dextrose has an elimination half-life of 15-20 minutes, electrolytes are not eliminated as a drug.
Not applicable; components are endogenous substances. Dextrose half-life ~15-20 min after infusion; electrolytes distribute and are cleared renally with half-lives dependent on renal function.
Dextrose is metabolized via glycolysis and oxidative phosphorylation. Acetate and gluconate are metabolized in the liver and other tissues to bicarbonate.
Dextrose undergoes glycolysis and the citric acid cycle; electrolytes are not metabolized but are excreted or incorporated into body pools.
Renal excretion of electrolytes and water; dextrose is metabolized to CO2 and water, with <0.5% excreted unchanged in urine.
ISOLYTE E in Dextrose 5% is a balanced electrolyte solution with glucose. Electrolytes are primarily excreted renally; water and dextrose are metabolized. Biliary/fecal excretion is negligible. Dextrose is metabolized to CO2 and water.
Negligible for electrolytes and dextrose (dextrose <5% bound to albumin).
None for electrolytes and dextrose; sodium, potassium, chloride, magnesium, acetate, and gluconate are free ions in solution.
Electrolytes distribute into total body water (0.6 L/kg); dextrose distributes into extracellular fluid (0.2 L/kg).
Sodium and chloride distribute primarily in extracellular fluid (~0.2 L/kg). Dextrose distributes in total body water (~0.6 L/kg). Potassium distributes in intracellular fluid (~0.6 L/kg after equilibration).
Intravenous: 100% by definition for all components.
100% intravenous; not administered by other routes.
No specific dose adjustment; use with caution in renal impairment due to risk of electrolyte disturbances. Monitor serum potassium and glucose. GFR <30 m L/min: avoid due to potassium content.
In renal impairment (e GFR < 30 m L/min/1.73m²), reduce total volume to 500-1000 m L/day with careful monitoring of potassium, sodium, and glucose; avoid if hyperkalemia or fluid overload.
No specific dose adjustment; use with caution in severe hepatic impairment due to potential for electrolyte imbalances. Monitor closely.
No specific dose adjustment for Child-Pugh class; monitor for fluid overload and electrolyte imbalances; in severe hepatic impairment, reduce volume to 500-1000 m L/day.
Intravenous infusion based on weight and clinical need. Typical maintenance: 100 m L/kg/day for first 10 kg, 50 m L/kg/day for 10-20 kg, 20 m L/kg/day for >20 kg. Adjust for dehydration or ongoing losses.
Weight-based: 20-50 m L/kg/day for maintenance; neonates and infants: 100-150 m L/kg/day; adjust based on glucose, electrolytes, and hydration status; maximum rate 4 m L/kg/hour for neonates.
Use with caution due to increased risk of fluid overload, electrolyte disturbances, and glucose intolerance. Start at lower infusion rates (e.g., 50-100 m L/h) and titrate based on clinical response and renal function.
Start with lower volumes (500-1000 m L/day) due to decreased renal function and risk of fluid overload; monitor serum electrolytes, glucose, and central venous pressure.
Not for use in patients with known hypersensitivity to corn or corn products (dextrose derived from corn). Solutions containing aluminum (trace) may be toxic to neonates or patients with renal impairment.
Not applicable; no FDA boxed warning exists for this product.
Risk of fluid overload, especially in patients with cardiac or renal impairment,Electrolyte imbalances (e.g., hyperkalemia, hypernatremia, hypomagnesemia) should be monitored,Use with caution in patients with severe renal impairment, hepatic failure, or conditions requiring sodium restriction,May cause hyperglycemia in diabetic patients or those with glucose intolerance,Do not administer simultaneously with blood or blood products through same tubing
Monitor serum electrolytes, fluid balance, and glucose levels; avoid fluid overload in patients with cardiac or renal impairment; risk of hyperglycemia in diabetic patients; use with caution in patients with metabolic alkalosis or hypokalemia.
Hyperglycemia or uncontrolled diabetes,Hyperkalemia, hypernatremia, or hypermagnesemia,Severe metabolic alkalosis,Known hypersensitivity to any component,Patients with anuria or severe oliguria
Hypersensitivity to any component; clinically significant hyperglycemia; severe metabolic acidosis; hyperkalemia (for potassium-containing formulations); hypermagnesemia; fluid overload conditions.
No specific food interactions. However, the dextrose component may affect blood glucose levels; patients on diabetic diets should monitor carbohydrate intake. Avoid excessive alcohol consumption due to risk of hypoglycemia or electrolyte imbalance.
No specific food interactions known. Monitor electrolyte intake in patients with electrolyte imbalances.
No teratogenic risk associated. Dextrose 5% and balanced electrolyte solution (Isolyte S) are not known to cause fetal harm. Use during pregnancy does not increase risk of congenital anomalies.
ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Dextrose and electrolytes are considered essential nutrients and are generally safe when used as indicated. However, administration during labor and delivery may cause fluid and electrolyte imbalances. First trimester risks are theoretical; second and third trimesters may involve risks of maternal hyperglycemia and fetal hyperinsulinemia if dextrose infusion is excessive. No specific teratogenicity reported.
Compatible with breastfeeding. Dextrose and electrolytes are normal constituents of breast milk. M/P ratio is not applicable as these are endogenous substances.
Dextrose and electrolytes are normal constituents of human milk. Following intravenous administration, concentrations in milk are expected to parallel maternal plasma levels. No specific M/P ratio is available. Use during breastfeeding is considered compatible; however, monitor for adverse effects in the infant such as electrolyte imbalance or hyperglycemia if maternal infusion is prolonged or high volume.
No specific dose adjustment required for pregnancy. Monitor for fluid overload and electrolyte imbalances due to increased plasma volume and GFR.
Pregnancy induces increased plasma volume and glomerular filtration rate, potentially diluting electrolytes and altering glucose metabolism. Dose adjustments may be required: consider lower dextrose infusion rates to avoid maternal hyperglycemia and fetal hyperinsulinemia. Monitor electrolytes closely; adjust potassium and magnesium supplementation as needed. No specific dose adjustment is universally recommended; individualize based on maternal weight, clinical status, and monitoring results.
ISOLYTE S with Dextrose 5% is an isotonic crystalloid solution containing electrolytes and dextrose. It should not be used for resuscitation in hemorrhagic shock as it may cause hyperglycemia and osmotic diuresis. Monitor serum glucose closely in diabetic patients. Do not administer simultaneously with blood products through the same tubing due to risk of hemolysis. Discard any unused portion; do not store partially used bags.
ISOLYTE E in DEXTROSE 5% is an isotonic crystalloid solution for IV administration. Contains electrolytes (Na, K, Mg, Cl, acetate, gluconate) and dextrose 5%. Use with caution in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum electrolytes, blood glucose, and fluid balance. Not for use as a sole source of nutrition. Do not administer if solution is discolored or contains particulates.
This solution is given through a vein to replace fluids and electrolytes.,Tell your doctor if you have diabetes, kidney problems, or heart failure.,You may need blood tests to monitor your sugar and electrolyte levels.,Report any swelling, shortness of breath, or pain at the IV site.
Inform your healthcare provider about all medical conditions, especially kidney disease, heart failure, or diabetes.,Report any signs of allergic reaction such as rash, itching, or trouble breathing.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Do not use if the bag is damaged or solution is cloudy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Isolyte S with Dextrose 5% is an intravenous solution providing electrolytes and calories. Dextrose supplies glucose for cellular energy metabolism, while electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure. Acetate and gluconate are metabolized to bicarbonate, providing alkalinizing effect.. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose determined by fluid and electrolyte requirements. Typical adult maintenance: 100-200 m L/h (2.4-4.8 L/day) depending on clinical status.. The standard adult dose of ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No teratogenic risk associated. Dextrose 5% and balanced electrolyte solution (Isolyte S) are not known to cause fetal harm. Use during pregnancy does not increase risk of congenit. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.